The information on this page is intended for journalists, press and media. Click YES to get to the newsroom. If you click NO you will come back to Mynewsdesk.com.
- Measures serum core-type fucosylated PSA, which was not possible in the past, with high speed and high sensitivity - Verified that fucosylated PSA index significantly rises in a man with high-risk prostate cancer - Adjunct in the conventional PSA test, high-risk prostate cancer can be effectively detected
The research team from Kindai University's Faculty of Medicine, in cooperation with DAIICHI SANKYO COMPANY, LIMITED, have verified at the preclinical stage that using the currently under-development anti-cancer drug, U3-1402*1, in combination with immune checkpoint inhibitors*2 has the potential to be an effective treatment.
Senior Administrator Masatoshi Kudo of Kindai University Faculty of Medicine, Department of Gastroenterology and Hepatology, with his research group has invented a new method (LEN-TACE) of treating patients with intractable multinodular or large liver cancers, particularly those with near advanced liver cancer.
When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.
To learn more about this, please read our Privacy Policy Users, which applies to our use of your personal data, and our Privacy Policy Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.
Please note that our Terms of Use apply to all use of our services.
You can withdraw your consent at any time by unsubscribing or deleting your account
Email sent to __email__. Click the link there to follow Japan University News.